JP2008509701A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008509701A5 JP2008509701A5 JP2007527563A JP2007527563A JP2008509701A5 JP 2008509701 A5 JP2008509701 A5 JP 2008509701A5 JP 2007527563 A JP2007527563 A JP 2007527563A JP 2007527563 A JP2007527563 A JP 2007527563A JP 2008509701 A5 JP2008509701 A5 JP 2008509701A5
- Authority
- JP
- Japan
- Prior art keywords
- conjugate
- subunits
- subunit
- compound
- base
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57404804P | 2004-05-24 | 2004-05-24 | |
| US60/574,048 | 2004-05-24 | ||
| US11/136,245 | 2005-05-23 | ||
| US11/136,245 US20050288246A1 (en) | 2004-05-24 | 2005-05-23 | Peptide conjugated, inosine-substituted antisense oligomer compound and method |
| PCT/US2005/018213 WO2005115479A2 (en) | 2004-05-24 | 2005-05-24 | Peptide conjugated, inosine-substituted antisense oligomer compound and method |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011130577A Division JP2011172596A (ja) | 2004-05-24 | 2011-06-10 | ペプチドが結合された、イノシン置換アンチセンスオリゴマー化合物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008509701A JP2008509701A (ja) | 2008-04-03 |
| JP2008509701A5 true JP2008509701A5 (cg-RX-API-DMAC7.html) | 2008-05-15 |
| JP4974890B2 JP4974890B2 (ja) | 2012-07-11 |
Family
ID=35451420
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007527563A Expired - Lifetime JP4974890B2 (ja) | 2004-05-24 | 2005-05-24 | ペプチドが結合された、イノシン置換アンチセンスオリゴマー化合物および方法 |
| JP2011130577A Withdrawn JP2011172596A (ja) | 2004-05-24 | 2011-06-10 | ペプチドが結合された、イノシン置換アンチセンスオリゴマー化合物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011130577A Withdrawn JP2011172596A (ja) | 2004-05-24 | 2011-06-10 | ペプチドが結合された、イノシン置換アンチセンスオリゴマー化合物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20050288246A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1765414B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP4974890B2 (cg-RX-API-DMAC7.html) |
| AT (1) | ATE529513T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2005247460B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2565103C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2375631T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2005115479A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004235396B2 (en) | 2003-04-29 | 2010-11-25 | Sarepta Therapeutics, Inc. | Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells |
| US20050288246A1 (en) | 2004-05-24 | 2005-12-29 | Iversen Patrick L | Peptide conjugated, inosine-substituted antisense oligomer compound and method |
| ES2627917T3 (es) | 2004-06-28 | 2017-08-01 | The University Of Western Australia | Oligonucleótidos no codificantes para la inducción de la omisión exónica y métodos de uso de los mismos |
| AU2006267051B2 (en) * | 2005-07-13 | 2013-03-07 | Sarepta Therapeutics, Inc. | Antisense antibacterial method and compound |
| US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
| LT2735568T (lt) * | 2006-05-10 | 2017-11-27 | Sarepta Therapeutics, Inc. | Oligonukleotido analogai, turintys katijonines jungtis tarp subvienetų |
| EP2046964B1 (en) * | 2006-07-12 | 2018-07-04 | The Regents of The University of California | Transducible delivery of nucleic acids by reversible phosphotriester charge neutralization protecting groups |
| AU2015200600B2 (en) * | 2007-06-29 | 2017-04-20 | Sarepta Therapeutics, Inc. | Tissue specific peptide conjugates and methods |
| US20100016215A1 (en) | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| USRE48468E1 (en) | 2007-10-26 | 2021-03-16 | Biomarin Technologies B.V. | Means and methods for counteracting muscle disorders |
| EP2209896B1 (en) | 2007-10-26 | 2017-03-01 | Dynavax Technologies Corporation | Methods and compositions for inhibition of immune responses and autoimmunity |
| NZ584793A (en) | 2007-10-26 | 2012-05-25 | Academisch Ziekenhuis Leiden | Means and methods for counteracting muscle disorders |
| EP2119783A1 (en) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
| EP3133160B1 (en) | 2008-10-24 | 2018-12-12 | Sarepta Therapeutics, Inc. | Exon skipping compositions for dmd |
| CN102459595A (zh) * | 2009-04-24 | 2012-05-16 | 普罗森那技术公司 | 用于治疗dmd的包含肌苷的寡核苷酸 |
| US20110269665A1 (en) | 2009-06-26 | 2011-11-03 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| AU2010306940A1 (en) | 2009-10-12 | 2012-06-07 | Smith, Larry | Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro |
| HUE040445T2 (hu) | 2009-11-12 | 2019-03-28 | Univ Western Australia | Antiszensz molekulák és eljárások betegségek kezelésére |
| US9506057B2 (en) | 2010-03-26 | 2016-11-29 | Integrated Dna Technologies, Inc. | Modifications for antisense compounds |
| KR101981705B1 (ko) | 2010-05-28 | 2019-05-24 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체 |
| CN103153346A (zh) | 2010-06-16 | 2013-06-12 | 戴纳瓦克斯技术公司 | 使用tlr7和/或tlr9抑制剂的治疗方法 |
| WO2012031243A2 (en) | 2010-09-03 | 2012-03-08 | Avi Biopharma, Inc. | dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS |
| CA2809457C (en) | 2010-09-07 | 2019-07-30 | Integrated Dna Technologies, Inc. | Modifications for antisense compounds |
| WO2012036159A1 (ja) | 2010-09-15 | 2012-03-22 | 日本精工株式会社 | ラジアルころ軸受用保持器 |
| US9161948B2 (en) | 2011-05-05 | 2015-10-20 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| AU2011367230B2 (en) * | 2011-05-05 | 2017-08-10 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| KR20140097398A (ko) | 2011-11-18 | 2014-08-06 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 기능적으로-변형된 올리고뉴클레오티드 및 이의 서브유니트 |
| CA2862628C (en) | 2012-01-27 | 2021-08-24 | Prosensa Technologies B.V. | Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy |
| JP2015529073A (ja) | 2012-08-20 | 2015-10-05 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 生物可逆性基を有するポリヌクレオチド |
| CA2889044A1 (en) | 2012-11-15 | 2014-05-22 | Roche Innovation Center Copenhagen A/S | Anti apob antisense conjugate compounds |
| US9217148B2 (en) | 2013-03-14 | 2015-12-22 | Sarepta Therapeutics, Inc. | Exon skipping compositions for treating muscular dystrophy |
| HK1220154A1 (zh) | 2013-03-15 | 2017-04-28 | Sarepta Therapeutics, Inc. | 改进的用於治疗肌营养不良的组合物 |
| CN113105559A (zh) * | 2013-12-12 | 2021-07-13 | 生命技术公司 | 增强转染的膜穿透性肽和组合物以及其使用方法 |
| US9790495B2 (en) | 2014-05-16 | 2017-10-17 | Oregon State University | Antisense antibacterial compounds and methods |
| CA2948568A1 (en) * | 2014-05-19 | 2015-11-26 | David Greenberg | Antisense antibacterial compounds and methods |
| WO2016108930A2 (en) | 2014-12-31 | 2016-07-07 | Geller Bruce L | Antisense antibacterial compounds and methods |
| US10849917B2 (en) | 2015-06-01 | 2020-12-01 | Sarepta Therapeutics, Inc. | Antisense-induced exon exclusion in type VII collagen |
| US11020417B2 (en) | 2015-06-04 | 2021-06-01 | Sarepta Therapeutics, Inc | Methods and compounds for treatment of lymphocyte-related diseases and conditions |
| EA201891419A1 (ru) * | 2015-12-15 | 2019-01-31 | Сарепта Терапьютикс, Инк. | Пептид-олигонуклеотидные конъюгаты |
| AU2016379399B2 (en) | 2015-12-23 | 2022-12-08 | Board Of Regents, The University Of Texas System | Antisense antibacterial compounds and methods |
| US11060089B2 (en) | 2016-04-18 | 2021-07-13 | Sarepta Therapeutics, Inc. | Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene |
| WO2018035380A1 (en) | 2016-08-17 | 2018-02-22 | Solstice Biologics, Ltd. | Polynucleotide constructs |
| NZ755416A (en) | 2016-12-19 | 2023-05-26 | Sarepta Therapeutics Inc | Exon skipping oligomer conjugates for muscular dystrophy |
| US11597744B2 (en) | 2017-06-30 | 2023-03-07 | Sirius Therapeutics, Inc. | Chiral phosphoramidite auxiliaries and methods of their use |
| US11555189B2 (en) | 2017-10-18 | 2023-01-17 | Sarepta Therapeutics, Inc. | Antisense oligomer compounds |
| US12049620B2 (en) | 2018-09-11 | 2024-07-30 | Amgen Inc. | Purification methods for guanine-rich oligonucleotides |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5525465A (en) | 1987-10-28 | 1996-06-11 | Howard Florey Institute Of Experimental Physiology And Medicine | Oligonucleotide-polyamide conjugates and methods of production and applications of the same |
| US5087617A (en) | 1989-02-15 | 1992-02-11 | Board Of Regents, The University Of Texas System | Methods and compositions for treatment of cancer using oligonucleotides |
| US5670617A (en) | 1989-12-21 | 1997-09-23 | Biogen Inc | Nucleic acid conjugates of tat-derived transport polypeptides |
| GB9209032D0 (en) | 1992-04-25 | 1992-06-10 | Ciba Geigy Ag | New peptide derivatives |
| EP0903408A3 (en) | 1992-08-21 | 2005-11-02 | Biogen, Inc. | Tat-derived transport polypeptide |
| BR9405707A (pt) * | 1993-01-07 | 1996-08-06 | Univ Jefferson | Inibiçao anti-sentido de c-myc para modular a proliferaçao de células de músculo liso |
| US5849727A (en) | 1996-06-28 | 1998-12-15 | Board Of Regents Of The University Of Nebraska | Compositions and methods for altering the biodistribution of biological agents |
| ES2210761T3 (es) * | 1997-05-21 | 2004-07-01 | The Board Of Trustees Of The Leland Stanford Junior University | Composicion y procedimiento para mejorar el transporte a traves de las membranas biologicas. |
| EP1109821A4 (en) | 1998-08-25 | 2002-04-03 | Human Genome Sciences Inc | 49 HUMAN-SECRETED PROTEINS |
| KR20010102992A (ko) * | 1999-01-29 | 2001-11-17 | 추후보정 | 표적 rna를 검출하는 비-침입적 방법 |
| KR20020013519A (ko) * | 1999-04-08 | 2002-02-20 | 추후제출 | 보편적 및/또는 축퇴성 염기를 포함하는 안티센스올리고뉴클레오티드 |
| US6875747B1 (en) | 1999-05-24 | 2005-04-05 | Avi Bio Pharma, Inc. | Antisense to c-myc for treatment of polycystic kidney disease |
| CA2374499A1 (en) | 1999-05-24 | 2000-11-30 | Avi Biopharma, Inc. | Antisense to c-myc for treatment of polycystic kidney disease |
| US6303573B1 (en) | 1999-06-07 | 2001-10-16 | The Burnham Institute | Heart homing peptides and methods of using same |
| WO2001013957A2 (en) | 1999-08-24 | 2001-03-01 | Cellgate, Inc. | Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties |
| US6669951B2 (en) | 1999-08-24 | 2003-12-30 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
| US7229961B2 (en) | 1999-08-24 | 2007-06-12 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into ocular tissues |
| US20030104622A1 (en) | 1999-09-01 | 2003-06-05 | Robbins Paul D. | Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses |
| US20020009491A1 (en) | 2000-02-14 | 2002-01-24 | Rothbard Jonathan B. | Compositions and methods for enhancing drug delivery across biological membranes and tissues |
| US20040170955A1 (en) | 2000-09-08 | 2004-09-02 | Wadih Arap | Human and mouse targeting peptides identified by phage display |
| US6559279B1 (en) | 2000-09-08 | 2003-05-06 | Isis Pharmaceuticals, Inc. | Process for preparing peptide derivatized oligomeric compounds |
| EP1191097A1 (en) | 2000-09-21 | 2002-03-27 | Leids Universitair Medisch Centrum | Induction of exon skipping in eukaryotic cells |
| WO2002038764A2 (en) | 2000-11-10 | 2002-05-16 | The Regents Of The University Of California | Il-17 receptor-like protein, uses thereof, and modulation of catabolic activity of il-17 cytokines on bone and cartilage |
| US7138238B2 (en) | 2001-02-06 | 2006-11-21 | Auburn University | Ligand sensor devices and uses thereof |
| AU2002250034A1 (en) | 2001-02-08 | 2002-08-19 | Sequitur, Inc. | Methods of light activated release 0f ligands from endosomes |
| DE60233137D1 (de) | 2001-02-16 | 2009-09-10 | Univ R | Transporter mit beabstandeten arginin-teilchen |
| US7456146B2 (en) | 2001-05-09 | 2008-11-25 | Ghc Research Development Corporation | Lytic peptide prodrugs |
| US20030087861A1 (en) * | 2001-05-17 | 2003-05-08 | Iversen Patrick L | Combined approach to treatment of cancer using a c-myc antisense oligomer |
| JP3735292B2 (ja) | 2001-07-26 | 2006-01-18 | 三菱重工業株式会社 | ダイエット効果のある健康食品および製剤 |
| US6645974B2 (en) | 2001-07-31 | 2003-11-11 | Merck & Co., Inc. | Androgen receptor modulators and methods for use thereof |
| US20090075377A1 (en) | 2001-08-03 | 2009-03-19 | Arbor Vita Corporation | Molecular interactions in cells |
| MXPA04005611A (es) | 2001-12-11 | 2005-04-19 | Cellgate Inc | Reactivos y conjugados de transporte de guanidinio. |
| WO2004084805A2 (en) | 2003-03-19 | 2004-10-07 | The J. David Gladstone Institutes | Acetylated tat polypeptides and methods of use thereof |
| AU2004235396B2 (en) | 2003-04-29 | 2010-11-25 | Sarepta Therapeutics, Inc. | Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells |
| DK1641822T3 (da) | 2003-07-08 | 2013-07-22 | Genentech Inc | Heterologe il-17-a/f-polypeptider og terapeutiske anvendelser deraf. |
| US20050203041A1 (en) | 2003-09-23 | 2005-09-15 | Mourich Dan V. | Antisense compound and method for selectively killing activated T cells |
| US20050222068A1 (en) | 2003-10-23 | 2005-10-06 | Mourich Dan V | Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells |
| US7786151B2 (en) | 2004-01-09 | 2010-08-31 | Kinopharma, Inc. | Therapeutic composition of treating abnormal splicing caused by the excessive kinase induction |
| WO2005072527A2 (en) | 2004-01-23 | 2005-08-11 | Avi Biopharma, Inc. | Antisense oligomers and methods for inducing immune tolerance and immunosuppression |
| WO2005077333A2 (en) | 2004-02-10 | 2005-08-25 | University Of Florida Research Foundation, Inc. | Gel-based delivery of recombinant adeno-associated virus vectors |
| US7402574B2 (en) | 2004-03-12 | 2008-07-22 | Avi Biopharma, Inc. | Antisense composition and method for treating cancer |
| US20050288246A1 (en) | 2004-05-24 | 2005-12-29 | Iversen Patrick L | Peptide conjugated, inosine-substituted antisense oligomer compound and method |
| WO2005117928A1 (en) | 2004-05-30 | 2005-12-15 | Cemines, Inc. | Compositions and methods for the treatment of skin cancer |
| ES2627917T3 (es) | 2004-06-28 | 2017-08-01 | The University Of Western Australia | Oligonucleótidos no codificantes para la inducción de la omisión exónica y métodos de uso de los mismos |
| JP2008504840A (ja) | 2004-06-30 | 2008-02-21 | アルニラム ファーマスーティカルズ インコーポレイテッド | 非リン酸骨格結合を含むオリゴヌクレオチド |
| WO2006029028A2 (en) | 2004-09-02 | 2006-03-16 | Cognosci, Inc. | Improved apo e analogs and methods for their use |
| WO2006031996A2 (en) | 2004-09-14 | 2006-03-23 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Targeting viruses using a modified sindbis glycoprotein |
| US8129352B2 (en) | 2004-09-16 | 2012-03-06 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating ssRNA viral infection |
| US8357664B2 (en) | 2004-10-26 | 2013-01-22 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
| US7524829B2 (en) | 2004-11-01 | 2009-04-28 | Avi Biopharma, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
| NZ538097A (en) | 2005-02-07 | 2006-07-28 | Ovita Ltd | Method and compositions for improving wound healing |
| WO2006086667A2 (en) | 2005-02-09 | 2006-08-17 | Avi Bio Pharma, Inc. | Antisense composition and method for treating muscle atrophy |
| CN101218254A (zh) | 2005-02-14 | 2008-07-09 | 惠氏公司 | 白介素-17f抗体及其它il-17f信号传递拮抗剂和它们的用途 |
| WO2006114478A1 (en) | 2005-04-26 | 2006-11-02 | Karyon-Ctt Ltd | Diagnostic and therapeutic agents |
| US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
| US7790694B2 (en) | 2005-07-13 | 2010-09-07 | Avi Biopharma Inc. | Antisense antibacterial method and compound |
| AU2006267051B2 (en) | 2005-07-13 | 2013-03-07 | Sarepta Therapeutics, Inc. | Antisense antibacterial method and compound |
| WO2007030691A2 (en) | 2005-09-08 | 2007-03-15 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating picornavirus infection |
| AU2006287530A1 (en) | 2005-09-08 | 2007-03-15 | Sarepta Therapeutics, Inc. | Antisense antiviral compound and method for treating picornavirus infection |
| US8137670B2 (en) | 2005-09-29 | 2012-03-20 | Medimmune, Llc | Method of identifying membrane IgE specific antibodies and use thereof for targeting IgE producing precursor cells |
| AU2006311586A1 (en) | 2005-11-08 | 2007-05-18 | Avi Biopharma, Inc. | Immunosuppression compound and treatment method |
| US8501704B2 (en) | 2005-11-08 | 2013-08-06 | Sarepta Therapeutics, Inc. | Immunosuppression compound and treatment method |
| CA2644262C (en) | 2006-03-07 | 2016-01-05 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating arenavirus infection |
| US8785407B2 (en) | 2006-05-10 | 2014-07-22 | Sarepta Therapeutics, Inc. | Antisense antiviral agent and method for treating ssRNA viral infection |
| LT2735568T (lt) | 2006-05-10 | 2017-11-27 | Sarepta Therapeutics, Inc. | Oligonukleotido analogai, turintys katijonines jungtis tarp subvienetų |
| CA2558160C (en) | 2006-06-30 | 2017-01-03 | Oligos Etc., Inc. | Antisense oligonucleotide targeting myostatin or fox01 for treatment of muscle wasting |
| JP6047270B2 (ja) | 2006-08-11 | 2016-12-21 | バイオマリン テクノロジーズ ベー.フェー. | Dnaリピートの不安定性に関連した遺伝的障害を治療するための方法及び手段 |
| US20080199961A1 (en) | 2006-08-25 | 2008-08-21 | Avi Biopharma, Inc. | ANTISENSE COMPOSITION AND METHOD FOR INHIBITION OF miRNA BIOGENESIS |
| US20080267978A1 (en) | 2006-08-28 | 2008-10-30 | Mary Zutter | Anti-angiogenic targets for cancer therapy |
| EP2066812A4 (en) | 2006-09-21 | 2010-04-28 | Univ Rochester | COMPOSITIONS AND METHODS RELATED TO PROTEIN SHIFT THERAPY FOR MYOTONE DYSTROPHY |
| FR2908999B1 (fr) | 2006-11-29 | 2012-04-27 | Biomerieux Sa | Nouveau medicament destine a l'inhibition, la prevention ou le traitement de la polyarthrite rhumatoide. |
| EP1938802A1 (en) | 2006-12-22 | 2008-07-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Interfering RNAs targeting pro-inflammatory cytokines |
| US20100016215A1 (en) | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| CA2691673A1 (en) | 2007-06-29 | 2009-01-08 | Avi Biopharma, Inc. | Tissue specific peptide conjugates and methods |
| WO2009026412A1 (en) | 2007-08-21 | 2009-02-26 | Children's Medical Center Corporation | Treatment of airway hyperreactivity |
| CA2710013A1 (en) | 2007-12-28 | 2009-07-09 | Avi Biopharma, Inc. | Immunomodulatory agents and methods of use |
| US20110130346A1 (en) | 2008-05-30 | 2011-06-02 | Isis Innovation Limited | Peptide conjugates for delvery of biologically active compounds |
| EP3133160B1 (en) | 2008-10-24 | 2018-12-12 | Sarepta Therapeutics, Inc. | Exon skipping compositions for dmd |
| US8592386B2 (en) | 2008-12-17 | 2013-11-26 | Sarepta Therapeutics, Inc. | Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis |
| US20110269665A1 (en) | 2009-06-26 | 2011-11-03 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| EP3023496B1 (en) | 2010-05-13 | 2020-07-29 | Sarepta Therapeutics, Inc. | Compounds which modulate interleukins 17 and 23 signaling activity |
| US9161948B2 (en) | 2011-05-05 | 2015-10-20 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
-
2005
- 2005-05-23 US US11/136,245 patent/US20050288246A1/en not_active Abandoned
- 2005-05-24 AU AU2005247460A patent/AU2005247460B2/en not_active Expired
- 2005-05-24 ES ES05754332T patent/ES2375631T3/es not_active Expired - Lifetime
- 2005-05-24 WO PCT/US2005/018213 patent/WO2005115479A2/en not_active Ceased
- 2005-05-24 AT AT05754332T patent/ATE529513T1/de not_active IP Right Cessation
- 2005-05-24 EP EP05754332A patent/EP1765414B1/en not_active Expired - Lifetime
- 2005-05-24 JP JP2007527563A patent/JP4974890B2/ja not_active Expired - Lifetime
- 2005-05-24 CA CA2565103A patent/CA2565103C/en not_active Expired - Lifetime
-
2008
- 2008-03-31 US US12/060,135 patent/US8053420B2/en active Active
-
2011
- 2011-06-10 JP JP2011130577A patent/JP2011172596A/ja not_active Withdrawn
- 2011-09-23 US US13/243,341 patent/US8877725B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12503698B2 (en) | GalNAc derivatives | |
| JP4974890B2 (ja) | ペプチドが結合された、イノシン置換アンチセンスオリゴマー化合物および方法 | |
| JP6715325B2 (ja) | siRNA、siRNAを含む医薬組成物及び結合体、並びにそれらの応用 | |
| US11939581B2 (en) | Methods and compositions for targeting PD-L1 | |
| JP2010532168A5 (cg-RX-API-DMAC7.html) | ||
| US20200385735A1 (en) | Modified gapmer oligonucleotides and methods of use | |
| JP7291418B2 (ja) | Pcsk9を標的としたアンチセンス核酸 | |
| JPH10510435A (ja) | B型肝炎ウイルス複製のアンチセンス阻害 | |
| JP7269968B2 (ja) | ペプチド担体上の多重オリゴヌクレオチド部分 | |
| JP2011530599A5 (cg-RX-API-DMAC7.html) | ||
| RU2015115721A (ru) | Связанные с пептидом морфолиновые антисмысловые олигонуклеотиды для лечения миотонической дистрофии | |
| ES2963814T3 (es) | Polímeros de ácido nucleico modificados con fosforotioato quelados para usar en combinación con un inhibidor de la polimerasa del VHB para el tratamiento de infecciones por los virus de la hepatitis B y la hepatitis D | |
| JP2010505831A5 (cg-RX-API-DMAC7.html) | ||
| JP2004537516A (ja) | アンチセンス浸透促進剤 | |
| JP2010501479A5 (cg-RX-API-DMAC7.html) | ||
| WO2018028494A1 (zh) | 吉西他滨ProTide乏氧活化前药及其应用 | |
| CA3037042A1 (en) | Modified oligonucleotides and methods of use | |
| JP2022535127A (ja) | アルファ-1アンチトリプシン欠乏症(aatd)の治療法 | |
| JP2023519518A5 (cg-RX-API-DMAC7.html) | ||
| AU2016317667A1 (en) | Modified antisense oligomers for exon inclusion in spinal muscular atrophy | |
| RU2014111179A (ru) | КОНЪЮГАТЫ ИНТЕРФЕРОНА λ1 И ПОЛИЭТИЛЕНГЛИКОЛЯ | |
| WO2016081773A2 (en) | Combination cancer therapy with c-met inhibitors and synthetic oligonucleotides | |
| TW202612708A (zh) | 組合治療 | |
| JP2023547274A5 (cg-RX-API-DMAC7.html) | ||
| CN116077673B (zh) | 一种f碱基白蛋白药物运载体系及其制备方法和用途 |